{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233268931746944.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2217/pgs.15.169"}},{"identifier":{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.2217/pgs.15.169"}}],"dc:title":[{"@value":"New Challenges and Promises in Solid Organ Transplantation Pharmacogenetics: the Genetic Variability of Proteins Involved in the Pharmacodynamics of Immunosuppressive Drugs"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233268931746947","@type":"Researcher","foaf:name":[{"@value":"Lucie Pouché"}],"jpcoar:affiliationName":[{"@value":"Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042Limoges, France"},{"@value":"CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042Limoges, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268931746945","@type":"Researcher","foaf:name":[{"@value":"Jana Stojanova"}],"jpcoar:affiliationName":[{"@value":"Laboratory of Chemical Carcinogenesis & Pharmacogenetics, University of Chile, Santiago, Chile"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268931746944","@type":"Researcher","foaf:name":[{"@value":"Pierre Marquet"}],"jpcoar:affiliationName":[{"@value":"Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042Limoges, France"},{"@value":"CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042Limoges, France"},{"@value":"Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France"},{"@value":"FHU SUPORT, 87000Limoges, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268931746946","@type":"Researcher","foaf:name":[{"@value":"Nicolas Picard"}],"jpcoar:affiliationName":[{"@value":"Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042Limoges, France"},{"@value":"CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042Limoges, France"},{"@value":"Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France"},{"@value":"FHU SUPORT, 87000Limoges, France"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14622416"},{"@type":"EISSN","@value":"17448042"}],"prism:publicationName":[{"@value":"Pharmacogenomics"}],"dc:publisher":[{"@value":"Informa UK Limited"}],"prism:publicationDate":"2016-01-22","prism:volume":"17","prism:number":"3","prism:startingPage":"277","prism:endingPage":"296"},"reviewed":"false","url":[{"@id":"https://www.tandfonline.com/doi/pdf/10.2217/pgs.15.169"}],"createdAt":"2016-01-22","modifiedAt":"2024-05-18","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360286994823497728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.2217/pgs.15.169"},{"@type":"CROSSREF","@value":"10.1097/ftd.0000000000000640_references_DOI_GjKdK0fb10AYMKvATgm53XTEJvC"}]}